ADC Therapeutics SA 2025 Annual Report: Key Investor Insights

Executive Summary

ADC Therapeutics SA (ADCT), a pharmaceutical company focused on oncology drugs, has filed its Annual Report (Form 10-K) for the fiscal year ending December 31, 2025. This report contains significant details that investors and shareholders should carefully consider, as several points could have material impact on the company’s share value and future prospects.

Key Financial and Operational Highlights

• Common Shares Outstanding: As of March 2, 2026, ADC Therapeutics had 127,044,356 common shares outstanding.
• Public Float: The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately \$136.4 million as of the last business day of the most recently completed second fiscal quarter.
• Listing: The company’s shares are traded on the New York Stock Exchange under the ticker ADCT.
• Filer Status: ADC Therapeutics is classified as a non-accelerated filer and a smaller reporting company. It is not an emerging growth company.
• SEC Reporting: The company has filed all required reports and is in compliance with SEC regulations, including submission of Interactive Data Files.
• Error Correction: The report notes a correction of an error to previously issued financial statements, though it did not require a recovery analysis of executive incentive compensation.

Forward-Looking Statements and Key Risks

ADC Therapeutics provides extensive forward-looking statements, highlighting several risk factors and uncertainties that could materially affect future performance and share price:

• Continued Net Losses: The company has incurred substantial net losses since inception and expects losses to continue for the foreseeable future. The need for additional capital to fund operations and execute its business plan is emphasized.
• Cash Flow Constraints: The purchase and sale agreement with HealthCare Royalty Management (HCR Agreement) negatively impacts the amount of cash that can be generated from sales and licensing agreements involving the company’s lead product, ZYNLONTA. This may also affect ADC Therapeutics’ attractiveness as an acquisition target.
• International Trade Uncertainties: Risks related to tariffs, sanctions, trade barriers, and most-favored nation drug pricing could affect operations and profitability.
• Clinical Trial Timing: Uncertainties remain regarding the company’s ability to complete clinical trials on expected timelines, which could impact regulatory submissions and product launches.
• Manufacturing Challenges: The complexity and difficulty of manufacturing products and candidates may affect supply, costs, and quality.
• Intellectual Property Risks: The company’s ability to obtain, maintain, and protect intellectual property rights is highlighted as a risk, along with potential infringement on others’ IP.
• Revenue Estimates: Future revenue, expenses, liquidity, and capital resource estimates are inherently uncertain.
• Product Liability: Potential product liability lawsuits and recalls are noted as material risks.

Corporate Governance and Proxy Statement

ADC Therapeutics intends to file a definitive proxy statement for its 2026 Annual General Meeting within 120 days of fiscal year end. Portions of this statement will be incorporated into Part III of the Annual Report, which may contain further details relevant to corporate governance, executive compensation, and director independence.

Shareholder Alerts and Price Sensitivity

• Correction of Prior Financial Statements: The report confirms that a correction was made to previously issued financial statements. While no recovery analysis of executive incentive-based compensation was required, shareholders should be alert to the fact that historical financials may have changed, which could affect valuation and investment decisions.
• Cash Constraints Related to ZYNLONTA: The HCR Agreement’s impact on cash flow from ZYNLONTA is particularly significant for investors, as this is the company’s lead commercial asset. Any limitations on cash generation or attractiveness to potential acquirers could influence share price.
• Ongoing Need for Capital: The company’s expectation to continue operating at a loss and its ongoing need to raise capital are critical factors for share price movement, especially in an uncertain market and funding environment.

Industry and Market Data

The report includes industry, market, and competitive data from both internal research and third-party publications. Investors should note that these figures are based on assumptions and projections subject to a high degree of uncertainty.

Disclaimer

Disclaimer: This article is based on ADC Therapeutics SA’s 2025 Annual Report and is intended for informational purposes only. The content does not constitute investment advice or a recommendation to buy or sell securities. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions.

View ADC Therapeutics SA Historical chart here